盐酸坦索罗辛是第三代超选择性长效α1受体抑制剂,由日本山之内制药研发成功,并于1992年7月获FDA批准上市。这是一种亚型高选择性的α1受体阻滞剂,专为治疗良性前列腺增生(BPH)而设计。盐酸坦索罗辛能阻断前列腺内的α1A受体以及膀胱内的α1A和α1D受体,从而导致上述部位平滑肌松弛,降低前列腺尿道压力,进而改善患者的排尿功能与临床症状。
用途盐酸坦索罗辛主要用于治疗前列腺增生症引起的排尿障碍,是专门针对良性前列腺增生的药物。它能特异性地抑制前列腺平滑肌的收缩,迅速缓解BPH相关的临床症状,疗效显著且不良反应较少。
PROBLEM TO BE SOLVED: To provide a method for simply producing (R)-(-)-5-[2-[2-(2-ethoxyphenoxy)ethylamino]-2-methylethyl]-2-methoxybenzenesulfonamide hydrochloride salt and an intermediate for the same at a reduced cost.
SOLUTION: This method for producing the optically active compound expressed by chemical formula (6) comprises subjecting a compound expressed by chemical formula (5) to optical resolution with an optical resolution agent which has an optically active saccharide derivative as an asymmetry identifying part.
COPYRIGHT: (C)2005,JPO&NCIPI